

**CA OPIOID SETTLEMENTS**  
**EXPENDITURE REPORTING FORM**

**SFY 2023 - 2024**

**Prepared on 2025-12-04 by the University of  
California, Los Angeles**

**Integrated Substance Use and Addictions Programs**



# CONTENTS

GENERAL INFORMATION	1
CA ABATEMENT ACCOUNT FUNDS INFORMATION	1
CA Abatement Payments: . . . . .	1
CA Abatement Reallocations: . . . . .	2
CA Abatement Expenditures: . . . . .	2
CA SUBDIVISION FUND INFORMATION	2
MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION	2
Mallinckrodt Bankruptcy Payments: . . . . .	2
Mallinckrodt Reallocations: . . . . .	3
Mallinckrodt Allowable Expenses: . . . . .	3
SUMMARY	3

# GENERAL INFORMATION

**Participating Subdivision:** San Pablo City  
**Subdivision Department/Organization:** San Pablo Police Department  
**Subdivision address:** 13880 San Pablo Avenue San Pablo CA 94806  
**Name of Preparer:** BRIAN P BUBAR  
**Preparer Title:** Police Chief  
**Preparer Email Address:** brianb@sanpabloca.gov  
**Preparer Phone Number:** 5102153262  
**This Subdivision received funds from:**  
Settlements & Mallinckrodt Pharmaceuticals Bankruptcy

# CA ABATEMENT ACCOUNT FUNDS INFORMATION

- Settlement(s):**
- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
  - Janssen Pharmaceuticals, Inc.

## CA Abatement Payments:

Payments Received by this Subdivision from the CA Abatement Account Fund

Settlement	CA Abatement Account Payments Received in SFY 23-24
Distributors	\$13,760.77
Janssen	\$6,216.99

---

**Is your Participating Subdivision depositing CA Abatement Accounts Fund payments from the National Settlement Administrator (Brown-Greer, PLC) into an interest-bearing account?:** No

### **CA Abatement Reallocations:**

**Reallocations Sent:** No funds received from the CA Abatement Account were reallocated to another Subdivision.

**Reallocations Received:** No funds received from the CA Abatement Account were reallocated from another Subdivision.

### **CA Abatement Expenditures:**

**How many total activities or programs funded by the funds from the CA Abatement Accounts Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?:** 0

## **CA SUBDIVISION FUND INFORMATION**

**Is your Participating Subdivision also a Plaintiff Subdivision?:** No

## **MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION**

**Did your Local Government receive funds from the Mallinckrodt Bankruptcy (NOAT II)?:** Yes

### **Mallinckrodt Bankruptcy Payments:**

**Total amount of funds received from NOAT II from July 1, 2023 – June 30, 2024:**

\$1,919.72

**Is your Local Government depositing Mallinckrodt Bankruptcy payments from NOAT II into an interest-bearing account?**

No

### **Mallinckrodt Reallocations:**

#### **Reallocations Sent:**

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated to another Subdivision.

#### **Reallocations Received:**

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated from another Subdivision.

### **Mallinckrodt Allowable Expenses:**

**Did your Local Government expend any bankruptcy funds during the period of July 1, 2023 – June 30, 2024?:** No

## **SUMMARY**

**All tables below are based on information reported during the SFY 2023-24 only.**

CA Abatement Account Fund Totals

<b>Settlement</b>	<b>Payment</b>	<b>Interest</b>	<b>Reallocations Sent</b>	<b>Reallocations Received</b>
Distributors	\$13,760.77	\$0.00	\$0.00	\$0.00
Janssen	\$6,216.99	\$0.00	\$0.00	\$0.00
Total	\$19,977.76	\$0.00	\$0.00	\$0.00

CA Abatement Account Activity Expenses

<b>Settlement</b>	<b>Activity Expenses</b>	<b>Indirect Costs</b>	<b>23/24 Encumbered Funds</b>	<b>22/23 Encumbered Funds</b>
Distributors	\$0.00	\$0.00	\$0.00	\$0.00
Janssen	\$0.00	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Totals

<b>Payment</b>	<b>Interest</b>	<b>Reallocations Sent</b>	<b>Reallocations Received</b>
\$1,919.72	\$0.00	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Expenses

<b>direct Costs</b>	<b>Indirect Costs</b>
\$0.00	\$0.00